Available now: Open-access interviews with experts on the COVID-19 pandemic: epidemiology, virus biology and possible vaccines and treatmentsView All
Dr. Sharad K. Verma GlaxoSmithKline, USA1 Talk
Sharad K. Verma is currently employed by GlaxoSmithKline as an Early Development Leader for the oncology therapy area. He received a B.S. in Chemical Education from the University of California, San Diego, working with Professor Trevor McMorris. After receiving his Ph.D. in Chemistry at the University of California, Irvine (synthetic... read moreorganic chemistry, Professor Harold Moore), he then spent two years at the University of California, Berkeley working on the synthesis of chiral heterocyclic natural products from amino acids with Emeritus Professor Henry Rapoport. After working at Bayer Pharmaceuticals in the Department of Chemistry Research for 5 years, Dr. Verma then joined GlaxoSmithKline in 2006. Dr. Verma has held various roles in project leadership and project management for oncology projects from discovery through early clinical development, targeting the areas of signal transduction, epigenetics, and immuno oncology. Dr. Verma is a reviewer for multiple journals, a steering member for multiple conference organizing committees, and is an NIH study section reviewer for the committees on Drug Discovery for the Nervous System, and Chemical Molecular Probes.